Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

4(66.7%)

Phase 3

1(16.7%)

Phase 2

1(16.7%)

6Total

Phase 1(4)

Phase 3(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT00002742Phase 3Completed

Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic Cancer

Role: lead

NCT00081549Phase 1Unknown

Aroplatin and Gemcitabine in Patients With Advanced Pancreatic Cancer Resistant to Standard Therapies

Role: lead

NCT00002403Phase 1Completed

Safety and Effectiveness of Zintevir (AR177) Given to HIV-Infected Patients

Role: lead

NCT00043199Phase 2Unknown

A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies

Role: lead

NCT00057395Phase 1Unknown

A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies

Role: lead

NCT00081536Phase 1Unknown

Aroplatin and Capecitabine in Patients With Advanced Colorectal Cancer Resistant to Standard Therapies

Role: lead

All 6 trials loaded